Response Genetics Expands Distribution of ResponseDX Testing into Mexico

Response Genetics, Inc. (Los Angeles, CA, USA) has completed a commercial agreement with DxM Diagnostico Molecular (DIFRA), a leading distributor for cancer testing in Mexico, to offer the ResponseDX testing services to patients throughout Mexico.

The agreement covers the ResponseDX Tissue of Origin test and other targeted molecular tests in the Response Genetics portfolio. The Tissue of Origin test is a US Food and Drug Administration (FDA; Silver Spring, MD, USA)-cleared test that uses gene expression analysis to provide a definitive diagnosis for poorly-differentiated or metastatic cancers without a clear primary origin. The test was acquired by Response Genetics in August 2013 and reintroduced to the market in February 2014.

Thomas Bologna, chairman and CEO of Response Genetics, said, "We believe the ResponseDX offerings, including our proprietary Tissue of Origin test provides differentiated content to effectively pursue international market opportunities. One of our initiatives is to increase access to our testing services both domestically and internationally. DIFRA will facilitate access to the full complement of our portfolio to Mexican oncologists and pathologists.

Response Genetics, Inc. Clinical Laboratory Improvement Amendments (CLIA)-certified clinical laboratory focused on the development and sale of molecular diagnostic testing services for cancer. The Company's technologies enable extraction and analysis of genetic information derived from tumor cells stored as formalin-fixed and paraffin-embedded specimens. The Company's principal customers include oncologists and pathologists.

Related Links:
Response Genetics, Inc.
US Food and Drug Administration